NASDAQ:MREO Mereo BioPharma Group (MREO) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free MREO Stock Alerts $2.78 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.76▼$2.8950-Day Range$2.58▼$3.9752-Week Range$0.92▼$4.36Volume748,361 shsAverage Volume1.59 million shsMarket Capitalization$347.47 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mereo BioPharma Group alerts: Email Address Mereo BioPharma Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside133.8% Upside$6.50 Price TargetShort InterestHealthy1.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.09Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.04 out of 5 starsMedical Sector551st out of 909 stocksPharmaceutical Preparations Industry250th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingMereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMereo BioPharma Group has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.86% of the outstanding shares of Mereo BioPharma Group have been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mereo BioPharma Group has recently increased by 6.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MREO. Previous Next 2.8 News and Social Media Coverage News SentimentMereo BioPharma Group has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Mereo BioPharma Group this week, compared to 0 articles on an average week.Search InterestOnly 5 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -23% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Mereo BioPharma Group is held by insiders.Percentage Held by Institutions62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 6.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Mereo BioPharma Group Stock (NASDAQ:MREO)Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Read More MREO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MREO Stock News HeadlinesApril 22, 2024 | americanbankingnews.comFY2024 Earnings Estimate for Mereo BioPharma Group plc Issued By Cantor Fitzgerald (NASDAQ:MREO)April 3, 2024 | globenewswire.comMereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 27, 2024 | globenewswire.comMereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 16, 2024 | finance.yahoo.comMREO Apr 2024 3.500 putMarch 16, 2024 | ca.finance.yahoo.comMREO Aug 2024 5.500 callMarch 16, 2024 | finance.yahoo.comMREO Apr 2024 1.500 callMarch 16, 2024 | finance.yahoo.comMREO Apr 2024 3.000 putApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 13, 2024 | seekingalpha.comVoyager Therapeutics gets new chief medical officerMarch 5, 2024 | globenewswire.comMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma ConferenceFebruary 23, 2024 | finance.yahoo.comMereo BioPharma Group plc (MREO)January 31, 2024 | finance.yahoo.comAM Best Assigns Preliminary Credit Assessment to Mereo Insurance LimitedJanuary 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Amarin (AMRN) and Mereo Biopharma Group Plc (MREO)December 20, 2023 | benzinga.comMereo BioPharma Group Stock (NASDAQ:MREO) Dividends: History, Yield and DatesDecember 19, 2023 | finance.yahoo.comHedge Funds Say These Penny Stocks Are Poised to ExplodeNovember 3, 2023 | finance.yahoo.comUltragenyx (RARE) Q3 Earnings and Revenues Miss EstimatesOctober 25, 2023 | finanznachrichten.deMereo BioPharma Group plc: Mereo BioPharma Reports on Recent Program Developments and Provides Financial UpdateOctober 25, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO)October 16, 2023 | benzinga.comWhy Is Mereo BioPharma Stock Trading Higher Today?October 14, 2023 | finance.yahoo.comUltragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)September 27, 2023 | finance.yahoo.comMREO Oct 2023 2.500 putSeptember 9, 2023 | msn.comCantor Fitzgerald Reiterates Mereo Biopharma Group Plc - ADR (MREO) Overweight RecommendationSeptember 7, 2023 | finance.yahoo.comMereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate UpdateAugust 19, 2023 | fool.comMereo BioPharma Group Plc (NASDAQ: MREO)August 11, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLCJuly 6, 2023 | msn.comMereo Biopharma Group Plc - ADR (MREO) Price Target Decreased by 7.69% to 4.08See More Headlines Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/07/2023Today4/24/2024Next Earnings (Estimated)6/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MREO CUSIPN/A CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$7.00 Low Stock Price Target$6.00 Potential Upside/Downside+133.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.09 Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual Sales$10 million Price / Sales34.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book6.95Miscellaneous Outstanding Shares124,990,000Free Float121,236,000Market Cap$347.47 million OptionableOptionable Beta0.85 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Denise Vera Scots-Knight Ph.D. (Age 65)Co-Founder, CEO & Executive Director Comp: $890.56kMr. Charles Edward Sermon (Age 55)Co-Founder, General Counsel, Business Development & Company Secretary Comp: $625.79kMs. Christine Fox CPA (Age 43)Chief Financial Officer Comp: $569.77kDr. John P. Richard M.B.A. (Age 67)Co-Founder & Chief Business Officer Dr. John A. Lewicki Ph.D. (Age 72)Chief Scientific Officer Dr. Jackie Parkin (Age 66)Senior VP & Therapeutic Head Ms. Alexandra Hughes-Wilson (Age 53)Chief of Patient Access & Commercial Planning Dr. Suba Krishnan (Age 59)Senior Vice President of Clinical Development Mr. Bo KaraSenior VP and Head of Pharmaceutical Development & CMCMore ExecutivesKey CompetitorsPrecigenNASDAQ:PGENUroGen PharmaNASDAQ:URGNRani TherapeuticsNASDAQ:RANIFibroBiologicsNASDAQ:FBLGAmarinNASDAQ:AMRNView All CompetitorsInstitutional OwnershipForefront Analytics LLCSold 29,525 shares on 2/15/2024Ownership: 0.029%Rubric Capital Management LPBought 1,936,877 shares on 2/14/2024Ownership: 10.843%NEOS Investment Management LLCBought 310,577 shares on 2/13/2024Ownership: 0.282%Primecap Management Co. CASold 25,000 shares on 2/9/2024Ownership: 0.043%Monaco Asset Management SAMBought 80,765 shares on 2/7/2024Ownership: 0.541%View All Institutional Transactions MREO Stock Analysis - Frequently Asked Questions Should I buy or sell Mereo BioPharma Group stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MREO shares. View MREO analyst ratings or view top-rated stocks. What is Mereo BioPharma Group's stock price target for 2024? 2 equities research analysts have issued 12-month target prices for Mereo BioPharma Group's shares. Their MREO share price targets range from $6.00 to $7.00. On average, they anticipate the company's share price to reach $6.50 in the next year. This suggests a possible upside of 133.8% from the stock's current price. View analysts price targets for MREO or view top-rated stocks among Wall Street analysts. How have MREO shares performed in 2024? Mereo BioPharma Group's stock was trading at $2.31 at the start of the year. Since then, MREO stock has increased by 20.3% and is now trading at $2.78. View the best growth stocks for 2024 here. When is Mereo BioPharma Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our MREO earnings forecast. How were Mereo BioPharma Group's earnings last quarter? Mereo BioPharma Group plc (NASDAQ:MREO) released its earnings results on Thursday, September, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). What ETFs hold Mereo BioPharma Group's stock? ETFs with the largest weight of Mereo BioPharma Group (NASDAQ:MREO) stock in their portfolio include Tema Oncology ETF (CANC) and Tema Cardiovascular and Metabolics ETF (HRTS). What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd). When did Mereo BioPharma Group IPO? Mereo BioPharma Group (MREO) raised $49 million in an IPO on the week of April 23rd 2018. The company issued 2,800,000 shares at $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers. How do I buy shares of Mereo BioPharma Group? Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MREO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
